 |
 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||
18 November 2003 | Volume 139 Issue 10 | Pages 817-823
Background: The incidence of hepatocellular carcinoma was reported to be increasing in the United States. However, alternate explanations were diagnostic or reclassification bias and changes in the demographic features of the general population.
Objective: To examine the temporal trends in the incidence of hepatocellular carcinoma.
Design: Retrospective cohort study.
Setting: Information collected by population-based registries of the Surveillance, Epidemiology, and End Results (SEER) program.
Patients: Persons given a diagnosis of hepatocellular carcinoma between 1975 and 1998.
Measurements: Linear Poisson multivariate regression model, controlling for differences in age, sex, race or ethnicity, and geographic region among patients with hepatocellular carcinoma and in the underlying population.
Results: The overall age-adjusted incidence rates of hepatocellular carcinoma increased from 1.4 per 100 000 in 1975 to 1977 to 3.0 per 100 000 in 1996 to 1998. There was a 25% increase during the last 3 years of the study compared with the preceding 3 years (1993 to 1995). The increase affected most age groups above 40 years, with the greatest increase in the 45- to 49-year-old age group. White men had the greatest increase (31%) in the last time period (1996 to 1998) compared with 1993 to 1995. The Poisson regression model confirmed an almost 2-fold increase in the incidence rate ratio for hepatocellular carcinoma between 1975 to 1978 and 1996 to 1998.
Conclusions: The incidence of hepatocellular carcinoma continues to increase rapidly in the United States, with rates increasing the fastest in white men 45 to 54 years of age. These findings are consistent with a true increase and could be explained by consequences of hepatitis C virus acquired during the 1960s and 1970s.
Editors' Notes
Context
Contribution
Implications
–The Editors
Author and Article Information
From The Houston Center for Quality of Care and Utilization Studies, Sections of Gastroenterology and Health Services Research at The Houston Veterans Affairs Medical Center, and Baylor College of Medicine, Houston, Texas; and the National Cancer Institute and U.S. Department of Health and Human Services, Bethesda, Maryland.
Grant Support: By the Health Services Research and Development Service, Office of Research and Development, Department of Veterans Affairs. Dr. El-Serag is a Veterans Affairs Health Services Research and Development Service Career Development awardee (RCD00-013-2).
Potential Financial Conflicts of Interest: None disclosed.
Requests for Single Reprints: Hashem B. El-Serag, MD, MPH, The Houston Veterans Affairs Medical Center, 2002 Holcombe Boulevard (152), Houston, TX 77030; e-mail, hasheme{at}bcm.tmc.edu.
Current Author Addresses Drs. El-Serag, Davila, and Petersen: The Houston Veterans Affairs Medical Center, 2002 Holcombe Boulevard (152), Houston, TX 77030.
Dr. McGlynn: National Cancer Institute, 6120 Executive Boulevard, Rockville, MD 20892-7234.
Author Contributions Conception and design: H.B. El-Serag.
Analysis and interpretation of the data: H.B. El-Serag, J.A. Davila, N.J. Petersen, K.A. McGlynn.
Drafting of the article: H.B. El-Serag.
Critical revision of the article for important intellectual content: H.B. El-Serag, J.A. Davila, K.A. McGlynn.
Final approval of the article: H.B. El-Serag, J.A. Davila, N.J. Petersen, K.A. McGlynn.
Statistical expertise: H.B. El-Serag, N.J. Petersen.
Administrative, technical, or logistic support: H.B. El-Serag. ARTICLE
The Continuing Increase in the Incidence of Hepatocellular Carcinoma in the United States: An Update
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  J. T. Heckman, M. B. deVera, J. W. Marsh, P. Fontes, N. B. Amesur, S. E. Holloway, M. Nalesnik, D. A. Geller, J. L. Steel, and T. C. Gamblin Bridging Locoregional Therapy for Hepatocellular Carcinoma Prior to Liver Transplantation Ann. Surg. Oncol., November 1, 2008; 15(11): 3169 - 3177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Benetti, A. Berenzi, M. Gambarotti, E. Garrafa, M. Gelati, E. Dessy, N. Portolani, T. Piardi, S. M. Giulini, A. Caruso, et al. Transforming Growth Factor-{beta}1 and CD105 Promote the Migration of Hepatocellular Carcinoma-Derived Endothelium Cancer Res., October 15, 2008; 68(20): 8626 - 8634. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. C. A. Chan, P. B. S. Lai, T. S. K. Mok, H. L. Y. Chan, C. Ding, S. W. Yeung, and Y. M. D. Lo Quantitative Analysis of Circulating Methylated DNA as a Biomarker for Hepatocellular Carcinoma Clin. Chem., September 1, 2008; 54(9): 1528 - 1536. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. Siegel, E. I. Cohen, A. Ocean, D. Lehrer, A. Goldenberg, J. J. Knox, H. Chen, S. Clark-Garvey, A. Weinberg, J. Mandeli, et al. Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma J. Clin. Oncol., June 20, 2008; 26(18): 2992 - 2998. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Tanaka, Y. Imai, N. Hiramatsu, Y. Ito, K. Imanaka, M. Oshita, T. Hijioka, K. Katayama, I. Yabuuchi, H. Yoshihara, et al. Declining Incidence of Hepatocellular Carcinoma in Osaka, Japan, from 1990 to 2003 Ann Intern Med, June 3, 2008; 148(11): 820 - 826. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Collette, F. Bonnetain, X. Paoletti, M. Doffoel, O. Bouche, J. L. Raoul, P. Rougier, F. Masskouri, L. Bedenne, and J. C. Barbare Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials Ann. Onc., June 1, 2008; 19(6): 1117 - 1126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. X. Zhu and G. K. Abou-Alfa Expanding the Treatment Options for Hepatocellular Carcinoma: Combining Transarterial Chemoembolization With Radiofrequency Ablation JAMA, April 9, 2008; 299(14): 1716 - 1718. [Full Text] [PDF]
|
|
|
|
 |
|
 A. X. Zhu, N. S. Holalkere, A. Muzikansky, K. Horgan, and D. V. Sahani Early Antiangiogenic Activity of Bevacizumab Evaluated by Computed Tomography Perfusion Scan in Patients with Advanced Hepatocellular Carcinoma Oncologist, February 1, 2008; 13(2): 120 - 125. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Jiang, Y. Gusev, I. Aderca, T. A. Mettler, D. M. Nagorney, D. J. Brackett, L. R. Roberts, and T. D. Schmittgen Association of MicroRNA Expression in Hepatocellular Carcinomas with Hepatitis Infection, Cirrhosis, and Patient Survival Clin. Cancer Res., January 15, 2008; 14(2): 419 - 427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Omata, H. Yoshida, J. Toyota, E. Tomita, S. Nishiguchi, N. Hayashi, S. Iino, I. Makino, K. Okita, G. Toda, et al. A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C Gut, December 1, 2007; 56(12): 1747 - 1753. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Sedjo, T. Byers, E. Barrera Jr., C. Cohen, E. T. H. Fontham, L. A. Newman, C. D. Runowicz, A. G. Thorson, M. J. Thun, E. Ward, et al. A Midpoint Assessment of the American Cancer Society Challenge Goal to Decrease Cancer Incidence by 25% Between 1992 and 2015 CA Cancer J Clin, November 1, 2007; 57(6): 326 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. B. El-Serag, M. Lau, K. Eschbach, J. Davila, and J. Goodwin Epidemiology of Hepatocellular Carcinoma in Hispanics in the United States Arch Intern Med, October 8, 2007; 167(18): 1983 - 1989. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. E. Woodall, C. R. Scoggins, J. Loehle, K. V. Ravindra, K. M. McMasters, and R. C. G. Martin Hepatic Imaging Characteristics Predict Overall Survival in Hepatocellular Carcinoma Ann. Surg. Oncol., October 1, 2007; 14(10): 2824 - 2830. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Meng, R. Henson, and T. Patel Chemotherapeutic stress selectively activates NF-{kappa}B-dependent AKT and VEGF expression in liver cancer-derived endothelial cells Am J Physiol Cell Physiol, August 1, 2007; 293(2): C749 - C760. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kato, M. Kanematsu, X. Zhang, M. Saio, H. Kondo, S. Goshima, and H. Fujita Computer-Aided Diagnosis of Hepatic Fibrosis: Preliminary Evaluation of MRI Texture Analysis Using the Finite Difference Method and an Artificial Neural Network Am. J. Roentgenol., July 1, 2007; 189(1): 117 - 122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. G. Martin II, J. Loehle, C. R. Scoggins, and K. M. McMasters Kentucky Hepatoma: Epidemiologic Variant or Same Problem in a Different Region? Arch Surg, May 1, 2007; 142(5): 431 - 437. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ikeda, H. Marusawa, Y. Osaki, T. Nakamura, N. Kitajima, Y. Yamashita, M. Kudo, T. Sato, and T. Chiba Antibody to Hepatitis B Core Antigen and Risk for Hepatitis C-Related Hepatocellular Carcinoma: A Prospective Study Ann Intern Med, May 1, 2007; 146(9): 649 - 656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. G. Rivenbark and W. B. Coleman The Use of Epigenetic Biomarkers for Preclinical Detection of Hepatocellular Carcinoma: Potential for Noninvasive Screening of High-Risk Populations Clin. Cancer Res., April 15, 2007; 13(8): 2309 - 2312. [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Rifai Ethical Impasses in the Care of Patients With Hepatitis C Psychosomatics, December 1, 2006; 47(6): 540 - 541. [Full Text] [PDF]
|
|
|
|
|
|
A. X. Zhu Systemic Therapy of Advanced Hepatocellular Carcinoma: How Hopeful Should We Be? Oncologist, July 1, 2006; 11(7): 790 - 800. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. McGlynn, R. E. Tarone, and H. B. El-Serag A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol. Biomarkers Prev., June 1, 2006; 15(6): 1198 - 1203. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. L. Armstrong, A. Wasley, E. P. Simard, G. M. McQuillan, W. L. Kuhnert, and M. J. Alter The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002 Ann Intern Med, May 16, 2006; 144(10): 705 - 714. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Hecht, A. E. Holland, G. M. Israel, W. Y. Hahn, D. C. Kim, A. B. West, J. S. Babb, B. Taouli, V. S. Lee, and G. A. Krinsky Hepatocellular Carcinoma in the Cirrhotic Liver: Gadolinium-enhanced 3D T1-weighted MR Imaging as a Stand-alone Sequence for Diagnosis. Radiology, May 1, 2006; 239(2): 438 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. X. Zhu, L. S. Blaszkowsky, D. P. Ryan, J. W. Clark, A. Muzikansky, K. Horgan, S. Sheehan, K. E. Hale, P. C. Enzinger, P. Bhargava, et al. Phase II Study of Gemcitabine and Oxaliplatin in Combination With Bevacizumab in Patients With Advanced Hepatocellular Carcinoma J. Clin. Oncol., April 20, 2006; 24(12): 1898 - 1903. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Rifai, J. K. Moles, and D. D. Short Hepatitis C Treatment Eligibility and Outcomes Among Patients With Psychiatric Illness Psychiatr Serv, April 1, 2006; 57(4): 570 - 572. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Schottenfeld and J. Beebe-Dimmer Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin, March 1, 2006; 56(2): 69 - 83. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Thomas and J. L. Abbruzzese Opportunities for Targeted Therapies in Hepatocellular Carcinoma J. Clin. Oncol., November 1, 2005; 23(31): 8093 - 8108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Schwartz, M. Sung, M. Schwartz, D. Lehrer, J. Mandeli, L. Liebes, A. Goldenberg, and M. Volm Thalidomide in Advanced Hepatocellular Carcinoma with Optional Low-Dose Interferon-{alpha}2a upon Progression Oncologist, October 1, 2005; 10(9): 718 - 727. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Barbare, O. Bouche, F. Bonnetain, J.-L. Raoul, P. Rougier, A. Abergel, V. Boige, B. Denis, A. Blanchi, A. Pariente, et al. Randomized Controlled Trial of Tamoxifen in Advanced Hepatocellular Carcinoma J. Clin. Oncol., July 1, 2005; 23(19): 4338 - 4346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-S. Lee, J. W. Grisham, and S. S. Thorgeirsson Comparative functional genomics for identifying models of human cancer Carcinogenesis, June 1, 2005; 26(6): 1013 - 1020. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. X. Zhu, C. S. Fuchs, J. W. Clark, A. Muzikansky, K. Taylor, S. Sheehan, K. Tam, E. Yung, M. H. Kulke, and D. P. Ryan A Phase II Study of Epirubicin and Thalidomide in Unresectable or Metastatic Hepatocellular Carcinoma Oncologist, June 1, 2005; 10(6): 392 - 398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Thomas and A. X. Zhu Hepatocellular Carcinoma: The Need for Progress J. Clin. Oncol., May 1, 2005; 23(13): 2892 - 2899. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Lambert, K. Bacher, L. Defreyne, F. Gemmel, H. Van Vlierberghe, J. M. Jeong, R. A. Dierckx, C. Van de Wiele, H. Thierens, and F. De Vos 188Re-HDD/Lipiodol Therapy for Hepatocellular Carcinoma: A Phase I Clinical Trial J. Nucl. Med., January 1, 2005; 46(1): 60 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Wands Prevention of Hepatocellular Carcinoma N. Engl. J. Med., October 7, 2004; 351(15): 1567 - 1570. [Full Text] [PDF]
|
|
|
|
|
|
J. J. Stark Prevention of Hepatocellular Carcinoma Ann Intern Med, July 6, 2004; 141(1): 77 - 77. [Full Text] [PDF]
|
|
|
|
|
|
Correction: The Continuing Increase in the Incidence of Hepatocellular Carcinoma in the United States Ann Intern Med, January 20, 2004; 140(2): 151 - 151. [Full Text] [PDF]
|
|
Article
